Latest Exploration News

Far Northern Resources has confirmed a combined JORC-compliant gold resource of over 117,000 ounces across its Northern Territory and Queensland projects, with Phase 2 drilling at Bridge Creek set to commence in September 2025.

Asian Battery Metals advances its Oval Cu-Ni-PGE project in Mongolia with significant down-dip extensions confirmed and new electromagnetic targets identified, setting the stage for an active Phase 4 drilling campaign.

Warriedar Resources reports encouraging assay results from 20 drillholes at its Golden Range Project, confirming extensions of gold mineralisation beyond current estimates at the M1 deposit and validating historical data at Valencia.

McLaren Minerals has reported very high-grade assay results from its Phase 1 drilling at the McLaren Titanium Project, confirming broad, continuous mineralisation and promising resource expansion just north of the current resource boundary.

New Murchison Gold Limited reveals significant high-grade gold intersections well below the current open pit at its Crown Prince Gold Mine, signaling promising underground mining potential and an extended mine life.

Gumtree Australia Markets Limited reports a transformational FY25 marked by a $6.8 million Capital Markets division sale, a near doubling of EBITDA, and promising expansions in transactional services and partnerships.

Swift Networks Group reported a 3.5% revenue decline in FY25 and a near doubling of losses, while raising $2.3 million and extending loan terms amid contract uncertainties.

Gold Road Resources reports a robust half-year profit surge driven by higher gold prices and sales, while advancing a proposed acquisition by Gold Fields with a shareholder vote set for September.

Sayona Mining delivered record lithium production and sales in FY25 but reported a $382 million loss due to asset impairments amid falling lithium prices. The company is poised for transformation with its imminent merger with Piedmont Lithium.

Sayona Mining delivered record lithium concentrate production and sales in FY25, driving revenue to $223 million despite a 16% drop in selling prices. The company also recorded a significant $271 million impairment on its North American Lithium assets amid weaker market conditions.

Noxopharm Limited reported a 36.5% increase in its annual loss to $4.88 million as it progressed preparations for its SOF-SKN™ clinical trial and secured $2.6 million through convertible notes. The biotech continues to invest heavily in its inflammation and oncology drug pipeline while managing liquidity and strategic partnerships.

Wellard Limited reported a net profit of US$1.3 million for FY2025, driven by operational improvements and strategic asset sales. With the sale of its last livestock vessels completed, the company plans to delist from the ASX and return surplus cash to shareholders.